Continuous Glucose Monitoring Using a New Subcutaneous Insulin Protocol for Mild to Moderate Diabetic Ketoacidosis

Launched by HEALTHPARTNERS INSTITUTE · Nov 15, 2024

Keywords

ClinConnect Summary

This clinical trial is exploring the use of continuous glucose monitoring (CGM) in patients with mild to moderate diabetic ketoacidosis (DKA) or hyperglycemia, who are being treated with a new insulin protocol at Regions Hospital. The goal is to see how well CGM works alongside regular blood sugar tests to help manage these conditions. Researchers will look at how many patients are willing to use a CGM device, how quickly it can be set up, how it affects the length of hospital stays, and how well it matches other blood sugar readings. The findings will help improve care strategies for DKA and related conditions.

To be eligible for this study, participants must be 18 years or older and present at Regions Hospital's emergency department, including those transferred from other hospitals. They need to be diagnosed with DKA or hyperosmolar hyperglycemic state (HHS) and meet specific medical criteria, such as having a certain blood acidity level. However, individuals with certain serious conditions, like severe heart failure or pregnancy, will not be able to participate. If you join the study, you'll be monitored closely to evaluate the effectiveness of the CGM and how it helps in managing your blood sugar levels during your hospital stay.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 18 years or older
• • Presents at Regions Hospital ED including transfers from other hospitals
• * Meets criteria for new subQ insulin protocol:
• • Diagnosis of DKA or HHS (hyperosmolar hyperglycemic state) and provider decision to initiate insulin
• • pH ≥ 7.1
• • HCO3 ≥ 12
• Exclusion Criteria:
• • Under 18 years of age
• * Excluded from new subQ protocol, specifically:
• • Acute CHF exacerbation
• • Acute MI (ACS/NSTEMI type 1 not demand ischemia)
• • CKD stage 4 or AKI with creatinine \> 3
• • ESLD
• • Pregnancy
• • Severe sepsis or septic shock
• • AMS \> if patient cannot consent
• • Euglycemic DKA